Towards Healthcare
Cell & Gene Therapy Quality Control Market Grows at 25.74% CAGR by 2034

Cell & Gene Therapy Quality Control Market to Surpass USD 22.8 Bn by 2034, Growing at 25.74% CAGR

Projections indicate that, the global cell & gene therapy quality control market will increase from USD 2.28 billion in 2024 to USD 22.81 billion by 2034, experiencing a CAGR of 25.74% over the next 10 years.The cell & gene therapy quality control market is growing due to it plays a significant role in ensuring that any cell or gene therapy that is directed to a patient is effective, safe, and meets a pre-defined set of quality parameters. The material must be systematically verified after it is manufactured, and over time, also ensure that the material remains effective through its intended shelf life. North America is dominated by a strong research and development ecosystem.

Content

  • Insight Code: 5854
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: July 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Rohan Patil is a seasoned market research professional with over 5 years of focused experience in the healthcare sector, bringing deep domain expertise, strategic foresight, and analytical precision to every project he undertakes.

He began his journey with Precedence Research, where he played a pivotal role in developing high-impact healthcare market reports. Today, Rohan leads research initiatives at Towards Healthcare, while also contributing to Statifacts, where he supports cross-industry analysis and data-driven storytelling.

Rohan’s core strengths lie in trend analysis and emerging technologies, regulatory monitoring and thought leadership through high-quality report writing. He excels at identifying future-ready opportunities and translating complex data into strategic recommendations. His work spans pharmaceuticals, biotechnology, medical devices, and digital health, assessing everything from market potential and competitive positioning to customer needs and regulatory shifts.

A trusted advisor and a relentless innovator, Rohan continues to push the boundaries of traditional market research, merging scientific rigor with commercial insight to stay ahead in a fast-evolving healthcare landscape.

Talk to us
FAQ's

The cell & gene therapy quality control market is projected to reach USD 22.81 billion by 2034, growing at a CAGR of 25.74% from 2024 to 2034.

North America is currently leading the cell & gene therapy quality control market due to the growing healthcare awareness and increasing government support.

The cell & gene therapy quality control market includes six segments such as by testing type, by product & service, by therapy type, by stage, by end user, and by region.

Some key players include Charles River Laboratories, Eurofins Scientific, Thermo Fisher Scientific, Merck KGaA (MilliporeSigma), and Sartorius AG.

Key trends include the rise of personalized medicine approaches and increasing regulatory approvals.

The typical Critical Quality Attributes (CQAs) of safety, purity, identity, quantity, potency, and stability, which are applied to biological products, also apply to cell and gene therapies.

DNA QC is the process of evaluating the quantity, purity, and integrity of the genomic DNA. First, once DNA is extracted from the patient sample, the DNA is checked to ensure it has been extracted without the contamination of proteins or organic solvents.

Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB, CDC.
Any Questions